Skip to content
Home/Companies/MedTech/CVRx

CVRx

MedTech·US·Exited 2021·Held 8yr
Entry
2013
Hold
8yr
Exit
2021

Who owns CVRx?

CVRx was owned by Ysios Capital Partners through Ysios BioFund II Innvierte (2016 vintage) from 2013 to 2021, exited via IPO.

Hand-verified · updated 2026-08-03

Ysios Capital Partners
Investor
Ysios Capital Partners
Ysios BioFund II Innvierte · 2016 · Life Sciences VC

Key facts

HQUS
SectorMedTech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2021

More from Ysios BioFund II Innvierte

Other portfolio companies in the same fund.

Anaconda Biomed
Anaconda Biomed
Active
MedTechES· 2017
Babyscripts
Babyscripts
Active
HealthTechUS· 2017
Prexton Therapeutics
Exited 2018
BiotechCH· 2017
to
Vivet Therapeutics
Vivet Therapeutics
Active
BiotechFR· 2017
Xeltis
Xeltis
Active
MedTechNL· 2017
AELIX Therapeutics
AELIX Therapeutics
Active
BiotechES· 2016

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany
Track CVRx

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy CVRx?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on CVRx.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue